ASCO looks for value in pricey cancer drugs
This article was originally published in Scrip
Executive Summary
The American Society of Clinical Oncology (ASCO) is developing a framework to help doctors and patients compared the relative value of cancer drugs, but while prices for vital therapies continue to rise, the effort will not focus on cost alone.